Abstract:e18003 Background: Our clinical observation from recurrent/metastatic head and neck patients who treated with platinum based combination after progression on pembrolizumab showed a striking response rate of 80% (8 out of 10 patients), this impressive ORR is dramatically higher than the historical ORR of 27% in the first-line setting. Our mouse model of ‘immune-cold’ head and neck cancer is developed to investigate the mechanism of sensitivity to platinum- based chemotherapy in PD-1 blockade-refractory head and neck cancer. Methods: For ‘immune-cold’ syngeneic model of HNSCC, C57BL/6 mice were injected with 5 × 10 4 MOC2 tumor cells in the right flank. After 11 days, mice with palpable tumors were randomized and treated concurrently with 4 groups (n = 5 per group): control, anti–PD1 antibody (200 mcg three times/week × 3 cycles), cisplatin (3mg/kg) +paclitaxel (5mg/kg) once a week x 3 cycles, or anti-PD1 antibody (200 mcg three times/week × 1 cycle) followed by cisplatin (3mg/kg) + paclitaxel (5mg/kg) once a week x 2 cycle. Cisplatin + paclitaxel arm received total of 4 cycles of treatment, while PD-1 followed by cisplatin and paclitaxel arm received total of 3 cycles of cisplatin and paclitaxel, this schedule was set up to maintain every 3 week regimen with same duration of treatment time to mimic patient’s treatment schedule in clinic setting. Tumor volume was measured 3 times per week. Results: Our initial pilot mouse model study showed similar tumor response seen in patient population. Starting on D24, average tumor size of PD1 inhibitor followed by cisplatin+paclitaxel group is significantly decreased compared to PD1 inhibitor or cisplatin+paclitaxel group and the difference is statistically significant. Most of mice in control and PD1 inhibitor group died at day 24 due to tumor progression. Our IHC data showed that the expression levels of immune markers such as CD8+, CD4+ and PDL1 in tumors treated with PD1 inhibitor followed by cisplatin and paclitaxel were increased, compared to almost no or scant expression (CD8+, CD4+) and lower expression (PDL1) in tumors treated with cisplatin and paclitaxel alone. With our expansion cohort, we will be further exploring key changes in immune signatures using both peripheral blood samples and tumor blocks for flow cytometry (myeloid/lymphoid subtypes, alterations in cytokine expression and circulating tumor DNA levels) and RNA sequencing analysis. Conclusions: We successfully established an ‘immune-cold’ mouse model of head and neck and reproduced similar tumor response seen in clinic. Preliminary data showing increased expression of immune makers such as CD8+, CD4+ and PDL warrants further investigation on tumor immune microenvironment remodeling as a potential mechanism of sensitivity to platinum-based chemotherapy in PD-1 blockade-refractory head and neck cancer.

Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner

Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on the Cancer Genome Atlas Dataset

IDDF2019-ABS-0174 Targeting Monocyte-Intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma

Efficacy and Mechanism of Hypofractionation Radiotherapy Combined with PD-1 Inhibitors in a Model of Head and Neck Melanoma

Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC

MHC-I and PD-L1 Expression is Associated with Decreased Tumor Outgrowth and is Radiotherapy-inducible in the Murine Head and Neck Squamous Cell Carcinoma Model MOC1

Targeting myeloid-derived suppressor cells to attenuate vasculogenic mimicry and synergistically enhance the anti-tumor effect of PD-1 inhibitor

Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients

Irradiation and Anti-Pd-l1 Treatment Synergistically Promote Antitumor Immunity in Mice.

Fe3O4 Nanoparticles That Modulate the Polarisation of Tumor-Associated Macrophages Synergize with Photothermal Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) to Enhance Anti-Tumor Therapy

Study on the sensitizing effect of SM-1 combined with irradiation on head and neck squamous cell carcinoma

Mechanisms of sensitivity to platinum-based chemotherapy in PD-1 blockade-refractory head and neck cancer.

Attenuated Salmonella carrying siRNA-PD-L1 and radiation combinatorial therapy induces tumor regression on HCC through T cell-mediated immuno-enhancement

Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade

Radiation therapy enhanced therapeutic efficacy of anti-PD1 against gastric cancer

Radiation and Anti-Pd-l1 Antibody Combinatorial Therapy Induces T Cell-Mediated Depletion of Myeloid-Derived Suppressor Cells and Tumor Regression

Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression.

Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma.

Mild hyperthermia upregulates PD-L1 in the tumor microenvironment and enhances antitumor efficacy of PD-L1 blockade in murine squamous cell carcinoma

Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers